Clinical gene therapy using recombinant adeno-associated virus vectors

@article{Mueller2008ClinicalGT,
  title={Clinical gene therapy using recombinant adeno-associated virus vectors},
  author={Christian Mueller and Terence R. Flotte},
  journal={Gene Therapy},
  year={2008},
  volume={15},
  pages={858-863}
}
Recombinant adeno-associated virus (rAAV) vectors possess a number of properties that may make them suitable for clinical gene therapy, including being based upon a virus for which there is no known pathology and a natural propensity to persist in human cells. Wild-type adeno-associated viruses (AAVs) are now known to be very diverse and ubiquitous in humans and nonhuman primates, which adds to the degree of confidence one may place in the natural history of AAV, namely that it has never been… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 158 CITATIONS

Gene Therapy for Rheumatoid Arthritis

VIEW 15 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2019

FILTER CITATIONS BY YEAR

2008
2019

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 11 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 44 REFERENCES

Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2007

A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.

  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2006

Similar Papers

Loading similar papers…